The detailed information for PTAB case with proceeding number IPR2025-01024 filed by Empower Clinic Services, LLC. (d/b/a Empower Pharmacy) against Eli Lilly & Co. on May 22, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2025-01024
Filing Date
May 22, 2025
Petitioner
Empower Clinic Services, LLC. (d/b/a Empower Pharmacy)
Respondent
Eli Lilly & Co.
Status
Pending
Respondent Application Number
14987791
Respondent Tech Center
1600
Respondent Patent Number
9474780

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Notice: Notice filing date accorded

Jun 20, 2025PAPERBOARD

Notice: Power of Attorney

Jun 12, 2025PAPERPATENT OWNER

Notice: Mandatory Notice

Jun 12, 2025PAPERPATENT OWNER

US Patent No. 9,474,780

May 22, 2025EXHIBITPETITIONER

Prosecution History of U.S. Patent No. 9,474,780

May 22, 2025EXHIBITPETITIONER

WO 2016111,971 International Search Report

May 22, 2025EXHIBITPETITIONER

WO 2016111,971 Written Opinion

May 22, 2025EXHIBITPETITIONER

WO 2011/119,657 A1 Publication

May 22, 2025EXHIBITPETITIONER

WO 2013/164,483 A1 Publication

May 22, 2025EXHIBITPETITIONER

WO 2006/097,537 A2 Publication

May 22, 2025EXHIBITPETITIONER

WO 2014/202,727 A1 Publication

May 22, 2025EXHIBITPETITIONER

Fields G. B. Introduction to peptide synthesis. Current protocols in protei

May 22, 2025EXHIBITPETITIONER

US 2015/0299281 A1 Publication

May 22, 2025EXHIBITPETITIONER

SAXENDA (liraglutide) injection drug label (Dec. 2014) (“SAXENDA”)

May 22, 2025EXHIBITPETITIONER

Nelson, D. L., et al., Chapters 4-5, 7, Lehninger Principles of Bio Part 1

May 22, 2025EXHIBITPETITIONER

Nelson, D. L., et al., Chapters 4-5, 7, Lehninger Principles of Bio Part 2

May 22, 2025EXHIBITPETITIONER

Segaloff, D. L., et al., Chapter 9: Internalization of Peptide Hormones and

May 22, 2025EXHIBITPETITIONER

Zhang Y., Baranov P.V., Atkins J.F., Gladyshev V.N. Pyrrolysine and selenoc

May 22, 2025EXHIBITPETITIONER

Merrifield R. B. Solid phase peptide synthesis. I. The synthesis of a tetra

May 22, 2025EXHIBITPETITIONER

Sawyer, W. H., Manning, M. Synthetic analogs of oxytocin and the vasopressi

May 22, 2025EXHIBITPETITIONER

Karten M.J., Rivier J.E. Gonadotropin-releasing hormone analog design. Stru

May 22, 2025EXHIBITPETITIONER

Garay R.P., El-Gewely R., Armstrong J.K, Garratty G., Richette P. Antibodie

May 22, 2025EXHIBITPETITIONER

Knudsen L.B. Liraglutide: the therapeutic promise from animal models. Int J

May 22, 2025EXHIBITPETITIONER

Ward B.P., et al. Peptide lipidation stabilizes structure to enhance biolog

May 22, 2025EXHIBITPETITIONER

Zhang L., Bulaj G. Converting peptides into drug leads by lipidation. Curr

May 22, 2025EXHIBITPETITIONER

Krauson A.J., He J., Wimley A.W., Hoffmann A.R., Wimley W.C. Synthetic mole

May 22, 2025EXHIBITPETITIONER

Lam K.S., et al. A new type of synthetic peptide library for identifying li

May 22, 2025EXHIBITPETITIONER

Liu T., Qian Z., Xiao Q., Pei D. High-throughput screening of one-bead-one-

May 22, 2025EXHIBITPETITIONER

Tautermann C.S. GPCR structures in drug design, emerging opportunities with

May 22, 2025EXHIBITPETITIONER

Donnelly D. The structure and function of the glucagon-like peptide-1 recep

May 22, 2025EXHIBITPETITIONER

Rajagopal, S., Rajagopal, K., & Lefkowitz, R. J. Teaching old receptors new

May 22, 2025EXHIBITPETITIONER

Yu Z, Jin T. New insights into the role of cAMP in the production and funct

May 22, 2025EXHIBITPETITIONER

Roed S.N., et al. Functional consequences of glucagon-like peptide-1 recept

May 22, 2025EXHIBITPETITIONER

Jorgensen R., Norklit Roed S., Heding A., Elling C. E. Beta-arrestin-2 as a

May 22, 2025EXHIBITPETITIONER

Jorgensen R., Kubale V., Vrecl M., Schwartz T.W., Elling C.E. Oxyntomodulin

May 22, 2025EXHIBITPETITIONER

Sonoda N, et al. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling

May 22, 2025EXHIBITPETITIONER

Siu F.Y., et al. Structure of the human glucagon class B G-protein-coupled

May 22, 2025EXHIBITPETITIONER

Hoare S.R. Mechanisms of peptide and nonpeptide ligand binding to Class B G

May 22, 2025EXHIBITPETITIONER

Hoare S. R. Allosteric modulators of class B G-protein-coupled receptors. C

May 22, 2025EXHIBITPETITIONER

Seino Y., Fukushima M., Yabe D. GIP and GLP-1, the two incretin hormones: S

May 22, 2025EXHIBITPETITIONER

Brown J.C., Mutt V., Pederson R.A. Further purification of a polypeptide de

May 22, 2025EXHIBITPETITIONER

Inagaki, N., et al. Gastric inhibitory polypeptide: Structure and chromosom

May 22, 2025EXHIBITPETITIONER

Dupre J., et al. Stimulation of insulin secretion by gastric inhibitory pol

May 22, 2025EXHIBITPETITIONER

Adrian T.E., Bloom S.R., Hermansen K., et al. Pancreatic polypeptide, gluca

May 22, 2025EXHIBITPETITIONER

Lund P.K., Goodman R.H., Dee P.C., Habener J.F. Pancreatic preproglucagon c

May 22, 2025EXHIBITPETITIONER

Hui H., Farilla L., Merkel P., Perfetti R. The short half-life of glucagon-

May 22, 2025EXHIBITPETITIONER

Singh A. K. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.

May 22, 2025EXHIBITPETITIONER

Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose‐depende

May 22, 2025EXHIBITPETITIONER

Montrose-Rafizadeh C., et al. High potency antagonists of the pancreatic gl

May 22, 2025EXHIBITPETITIONER

VICTOZA (liraglutide) injection drug label (Jan. 2010) (“VICTOZA”)

May 22, 2025EXHIBITPETITIONER

Bode B. Liraglutide: a review of the first once-daily GLP-1 receptor agonis

May 22, 2025EXHIBITPETITIONER

Neumiller J.J., Campbell R.K. Liraglutide: a once-daily incretin mimetic fo

May 22, 2025EXHIBITPETITIONER

BYDUREON (exenatide) injection drug label (Jan. 2012) (“BYDUREON”)

May 22, 2025EXHIBITPETITIONER

BYETTA (exenatide) injection drug label (Apr. 2005) (“BYETTA”)

May 22, 2025EXHIBITPETITIONER

TRULICITY (dulaglutide) injection drug label (Sept. 2014) (“TRULICITY”).

May 22, 2025EXHIBITPETITIONER

ADLYXIN (lixisenatide) injection drug label (Jul. 2016) (“ADLYXIN”)

May 22, 2025EXHIBITPETITIONER

OZEMPIC (semaglutide) injection drug label (Dec. 2017) (“OZEMPIC”)

May 22, 2025EXHIBITPETITIONER

Monami M., Dicembrini I., Marchionni N., Rotella C.M., Mannucci E. Effects

May 22, 2025EXHIBITPETITIONER

Day J.W., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in

May 22, 2025EXHIBITPETITIONER

Pocai A., et al. Glucagon-like peptide 1/glucagon receptor dual agonism rev

May 22, 2025EXHIBITPETITIONER

Finan B., Ma T., et al. Unimolecular dual incretins maximize metabolic bene

May 22, 2025EXHIBITPETITIONER

Stenkamp R.E., et al. Crystal structure of rhodopsin: A G protein-coupled r

May 22, 2025EXHIBITPETITIONER

Rasmussen S.G., et al. Crystal structure of the human beta2 adrenergic G-pr

May 22, 2025EXHIBITPETITIONER

Stevens R. C., et al. The GPCR Network: a large-scale collaboration to dete

May 22, 2025EXHIBITPETITIONER

Berman, H. M., et al. The Protein Data Bank. Nuc Acids Res, 2000; 28(1), 23

May 22, 2025EXHIBITPETITIONER

Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler M

May 22, 2025EXHIBITPETITIONER

Adelhorst K., Hedegaard B.B., Knudsen L.B., Kirk O. Structure-activity stud

May 22, 2025EXHIBITPETITIONER

Manandhar B., Ahn J.M. Glucagon-like peptide-1 (GLP-1) analogs: recent adva

May 22, 2025EXHIBITPETITIONER

Thum A., Hupe-Sodmann K., et al. Endoproteolysis by isolated membrane pepti

May 22, 2025EXHIBITPETITIONER

Fineman M. S., et al., Clinical relevance of anti-exenatide antibodies: saf

May 22, 2025EXHIBITPETITIONER

Buse J. B., et al., Liraglutide Treatment Is Associated with a Low Frequenc

May 22, 2025EXHIBITPETITIONER

Doyle M.E., et al. The importance of the nine-amino acid C-terminal sequenc

May 22, 2025EXHIBITPETITIONER

Simonsen L., Holst J.J., Madsen, K., Deacon C.F. The C-terminal extension o

May 22, 2025EXHIBITPETITIONER

Tatarkiewicz, K., et al., A novel long-acting glucose-dependent insulinotro

May 22, 2025EXHIBITPETITIONER

WO 2015/067,715 A2 Publication

May 22, 2025EXHIBITPETITIONER

Keen, H. et al. Human insulin produced by recombinant DNA technology: safet

May 22, 2025EXHIBITPETITIONER

Curriculum Vitae of Dr. Virginia W. Cornish, Ph.D.

May 22, 2025EXHIBITPETITIONER

Declaration of Dr. Virginia W. Cornish, Ph.D.

May 22, 2025EXHIBITPETITIONER

Notice: Power of Attorney

May 22, 2025PAPERPETITIONER

Petition: as filed

May 22, 2025PAPERPETITIONER